Expression of ornithine decarboxylase in peripheral blood mononuclear cells from patients with pancreatic adenocarcinoma: A preliminary report

Ruiz-Barrios,Lizeth Del Refugio; Pineda-Razo,Tomás Daniel; Hernández-Flores,Georgina; Ortiz-Lazareno,Pablo Cesar; Bravo-Cuéllar,Alejandro; Macias-Lamas,Adriana Macaria; Parra-Saavedra,Karina Jeanette; Palafox-Mariscal,Luis Arturo; Aguilar-Lemarroy,Adriana; Jave-Suárez,Luis Felipe; Villaseñor-García,María Martha

doi:10.3892/br.2024.1726

Expression of ornithine decarboxylase in peripheral blood mononuclear cells from patients with pancreatic adenocarcinoma: A preliminary report

Authors:
- Lizeth Del Refugio Ruiz-Barrios
- Tomás Daniel Pineda-Razo
- Georgina Hernández-Flores
- Pablo Cesar Ortiz-Lazareno
- Alejandro Bravo-Cuéllar
- Adriana Macaria Macias-Lamas
- Karina Jeanette Parra-Saavedra
- Luis Arturo Palafox-Mariscal
- Adriana Aguilar-Lemarroy
- Luis Felipe Jave-Suárez
- María Martha Villaseñor-García
View Affiliations

Affiliations: Oncology Service, High Specialty Medical Unit, Western National Medical Center, Mexican Social Security Institute, Guadalajara 44340, United Mexican States, Division of Immunology, Western Biomedical Research Center (CIBO), Mexican Social Security Institute, Guadalajara 44340, United Mexican States, Department of Pharmacobiology, University Center for Exact Sciences and Engineering (CUCEI) University of Guadalajara (UdeG), Guadalajara 44240, United Mexican States, Doctoral Program in Biomedical Science Orientation Immunology, University Center for Health Science (CUCS), University of Guadalajara (UdeG), Guadalajara 44430, United Mexican States
Published online on: January 17, 2024 https://doi.org/10.3892/br.2024.1726
Article Number: 38
Copyright: © Ruiz-Barrios et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ductal adenocarcinoma represents 90‑95% of pancreatic cancer (PC) cases and it is an aggressive disease with asymptomatic evolution at early stages, non‑specific symptoms and a typical late diagnosis with a 5‑year survival rate estimated to be 8%. A window of opportunity lies in early diagnosis as there are currently no reliable biomarkers. CA 19‑9 is one of the most frequently used biomarkers of PC, with 75 and 77.6% sensitivity (Se) and specificity (Sp), respectively, and the carcinoembryonic antigen (CEA) shows 39.5 and 81.3% of Se and Sp, respectively. A case‑control study was conducted including adult patients with a histological diagnosis of PC (n=11) without previous treatment at the Oncology Service of the CMNO‑IMSS between 2019 and 2020, and a control group of adult volunteers (n=11) who were clinically healthy or with controlled disease including hypertension, hypothyroidism and diabetes. Clinical, laboratory and sociodemographic data as well as blood, urine and saliva samples were collected following patient consent. Polyamines were quantified using high‑performance liquid chromatography with fluorescence detection, CA 19‑9 and CEA were evaluated using enzyme‑linked immunosorbent assay, and the protein expression of ornithine decarboxylase (ODC) was evaluated using western blotting. Polyamine metabolism and modulation by means of ODC were increased in the serum and saliva of patients with PC, and the expression of ODC alone was increased in peripheral blood mononuclear cells (PBMCs). The present study focused on the evaluation of putrescine, spermine, spermidine and ODC in PBMCs associated with CA 19‑9 and CEA as an auxiliary tool in PC diagnosis.

View Figures

View References

1	American Cancer Society. Key Statistics for Pancreatic Cancer. https://www.cancer.org/content/dam/CRC/PDF/Public/8778.00.pdf. Accessed February 20, 2022.
2	Zhang L, Sanagapalli S and Stoita A: Challenges in diagnosis of pancreatic cancer. World J Gastroenterol. 24:2047–2060. 2018.PubMed/NCBI View Article : Google Scholar
3	Poruk KE, Firpo MA, Adler DG and Mulvihill SJ: Screening for pancreatic cancer: Why, how, and who? Ann Surg. 257:17–26. 2013.PubMed/NCBI View Article : Google Scholar
4	Globocan: Global Cancer Statistics in Mexico. Journal 2021: 2020. https://gco.iarc.fr/today/data/factsheets/populations/484-mexico-fact-sheets.pdf. Accessed December 2021.
5	Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, et al: Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 467:1114–1117. 2010.PubMed/NCBI View Article : Google Scholar
6	Asai Y, Itoi T, Sugimoto M, Sofuni A, Tsuchiya T, Tanaka R, Tonozuka R, Honjo M, Mukai S, Fujita M, et al: Elevated polyamines in saliva of pancreatic cancer. Cancers (Basels). 10(43)2018.PubMed/NCBI View Article : Google Scholar
7	Ballehaninna UK and Chamberlain RS: The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 3:105–119. 2012.PubMed/NCBI View Article : Google Scholar
8	O'Neill RS and Stoita A: Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket? World J Gastroenterol. 27:4045–4087. 2021.PubMed/NCBI View Article : Google Scholar
9	Chang CY, Huang SP, Chiu HM, Lee YC, Chen MF and Lin JT: Low efficacy of serum levels of CA 19-9 in prediction of malignant diseases in asymptomatic population in Taiwan. Hepatogastroenterology. 53:1–4. 2006.PubMed/NCBI
10	Hartwig W, Strobel O, Hinz U, Fritz S, Hackert T, Roth C, Büchler MW and Werner J: CA19-9 in potentially resectable pancreatic cancer: Perspective to adjust surgical and perioperative therapy. Ann Surg Oncol. 20:2188–2196. 2013.PubMed/NCBI View Article : Google Scholar
11	Wingren C, Sandström A, Segersvärd R, Carlsson A, Andersson R, Löhr M and Borrebaeck CA: Identification of serum biomarker signatures associated with pancreatic cancer. Cancer Res. 72:2481–2490. 2012.PubMed/NCBI View Article : Google Scholar
12	Hermida Lazcano I, Sánchez Tejero E, Nerín Sánchez C, Cordero Bernabé R, Mora Escudero I and Pinar Sánchez J: Tumor markers. Marcadores Tumorales. Rev Clín Med Fam. 9:31–42. 2016.
13	Goonetilleke KS and Siriwardena AK: Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 33:266–270. 2007.PubMed/NCBI View Article : Google Scholar
14	Menéndez-Sánchez P, Villarejo-Campos P, Padilla-Valverde D, Menéndez-Rubio JM and Rodríguez-Montes JA: Tumor markers in colorectal cancer. Cir Cir. 81:169–175. 2013.PubMed/NCBI(In Spanish).
15	Tellez-Avila F, García-Osogobio S and Residente R: The carcinoembryonic antigen: by the way a well-known friend. Rev Invest Clin. 57:814–819. 2005.(In Spanish).
16	Irigoyen Oyarzabal AM, Amiguet García JA, López Vivanco G, Genollá Subirats J, Muñoz Villafranca MC, Ojembarrena Martínez E and Liso Irurzun P: Tumoral markers and acute-phase reactants in the diagnosis of pancreatic cancer. Gastroenterol Hepatol. 26:624–629. 2003.PubMed/NCBI View Article : Google Scholar : (In Spanish).
17	Guasco Herrera C, Chávez Servín JL, Ferriz Martínez RA, de la Torre Carbot K, Elton Puente E and García Gasca T: Polyamines: Little Giants of Metabolic Regulation. REB. 33:51–57. 2014.(In Spanish).
18	Wallace HM, Fraser AV and Hughes A: A perspective of polyamine metabolism. Biochem J. 376(Pt 1):1–14. 2003.PubMed/NCBI View Article : Google Scholar
19	Medina MA, Quesada AR, Núñez de Castro I and Sánchez-Jiménez F: Histamine, polyamines, and cancer. Biochem Pharmacol. 57:1341–1344. 1999.PubMed/NCBI View Article : Google Scholar
20	Madan M, Patel A, Skruber K, Geerts D, Altomare DA and Iv OP: ATP13A3 and caveolin-1 as potential biomarkers for difluoromethylornithine-based therapies in pancreatic cancers. Am J Cancer Res. 6:1231–1252. 2016.PubMed/NCBI
21	Niemi RJ, Roine AN, Häkkinen MR, Kumpulainen PS, Keinänen TA, Vepsäläinen JJ, Lehtimäki T, Oksala NK and Mäenpää JU: Urinary polyamines as biomarkers for ovarian cancer. Int J Gynecol Cancer. 27:1360–1366. 2017.PubMed/NCBI View Article : Google Scholar
22	Kawakita M, Hiramatsu K, Yanagiya M, Doi Y and Kosaka M: Determination of N¹,N¹²-diacetylspermine in urine: A novel tumor marker. Methods Mol Biol. 720:367–378. 2011.PubMed/NCBI View Article : Google Scholar
23	Umemori Y, Ohe Y, Kuribayashi K, Tsuji N, Nishidate T, Kameshima H, Hirata K and Watanabe N: Evaluating the utility of N1,N12-diacetylspermine and N1,N8-diacetylspermidine in urine as tumor markers for breast and colorectal cancers. Clin Chim Acta. 411:1894–1899. 2010.PubMed/NCBI View Article : Google Scholar
24	Takahashi Y, Sakaguchi K, Horio H, Hiramatsu K, Moriya S, Takahashi K and Kawakita M: Urinary N1, N12-diacetylspermine is a non-invasive marker for the diagnosis and prognosis of non-small-cell lung cancer. Br J Cancer. 113:1493–1501. 2015.PubMed/NCBI View Article : Google Scholar
25	Tsoi TH, Chan CF, Chan WL, Chiu KF, Wong WT, Ng CF and Wong KL: Urinary Polyamines: A pilot study on their roles as prostate cancer detection biomarkers. PLoS One. 11(e0162217)2016.PubMed/NCBI View Article : Google Scholar
26	Sugimoto M, Wong DT, Hirayama A, Soga T and Tomita M: Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics. 6:78–95. 2010.PubMed/NCBI View Article : Google Scholar
27	Soda K: The mechanisms by which polyamines accelerate tumor spread. J Exp Clin Cancer Res. 30(95)2011.PubMed/NCBI View Article : Google Scholar
28	Massaro C, Thomas J and Phanstiel Iv O: Investigation of polyamine metabolism and homeostasis in pancreatic cancers. Med Sci (Basel). 5(32)2017.PubMed/NCBI View Article : Google Scholar
29	Venza M, Visalli M, Cicciu D and Teti D: Determination of polyamines in human saliva by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl. 757:111–117. 2001.PubMed/NCBI View Article : Google Scholar
30	Cruz-Galvez CC, Ortiz-Lazareno PC, Pedraza-Brindis EJ, Villasenor-Garcia MM, Reyes-Uribe E, Bravo-Hernandez A, Solis-Martinez RA, Cancino-Marentes M, Rodriguez-Padilla C, Bravo-Cuellar A and Hernandez-Flores G: Pentoxifylline enhances the apoptotic effect of carboplatin in Y79 retinoblastoma cells. In Vivo. 33:401–412. 2019.PubMed/NCBI View Article : Google Scholar
31	Shmulewitz D, Aharonovich E, Witkiewitz K, Anton RF, Kranzler HR, Scodes J, Mann KF, Wall MM and Hasin D: Alcohol Clinical Trials Initiative (ACTIVE Group). The World Health Organization Risk Drinking Levels Measure of Alcohol Consumption: Prevalence and Health Correlates in Nationally Representative Surveys of U.S. Adults, 2001-2002 and 2012-2013. Am J Psychiatry. 178:548–559. 2021.PubMed/NCBI View Article : Google Scholar
32	Lukic S, Mijac D, Filipovic B, Sokic-Milutinovic A, Tomasevic R, Krstic M and Milosavljevic T: Chronic abdominal pain: Gastroenterologist approach. Dig Dis. 40:181–186. 2022.PubMed/NCBI View Article : Google Scholar
33	Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and Winchester DP: The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more ‘personalized’ approach to cancer staging. CA Cancer J Clin. 67:93–99. 2017.PubMed/NCBI View Article : Google Scholar
34	Rawla P, Sunkara T and Gaduputi V: Epidemiology of pancreatic cancer: Global trends, etiology and risk factors. World J Oncol. 10:10–27. 2019.PubMed/NCBI View Article : Google Scholar
35	McNamara KM, Gobert AP and Wilson KT: The role of polyamines in gastric cancer. Oncogene. 40:4399–4412. 2021.PubMed/NCBI View Article : Google Scholar
36	Holbert CE, Cullen MT, Casero RA Jr and Stewart TM: Polyamines in cancer: Integrating organismal metabolism and antitumour immunity. Nat Rev Cancer. 22:467–480. 2022.PubMed/NCBI View Article : Google Scholar
37	Kenner BJ, Chari ST, Maitra A, Srivastava S, Cleeter DF, Go VL, Rothschild LJ and Goldberg AE: Early detection of pancreatic cancer-a defined future using lessons from other cancers: A white paper. Pancreas. 45:1073–1079. 2016.PubMed/NCBI View Article : Google Scholar
38	Li Y, Li Y and Huang C: Circulating miRNAs Increasing the Risk of Cancer. In: Cancer and Noncoding RNAs. Chakrabarti J and Mitra S (eds). Vol. 1. Academic Press, Boston, pp79-94, 2018.